Indian drugmaker Lupin misses quarterly profit estimates as costs rise [Reuters]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Reuters
on Monday, as higher raw material costs more than offset strong demand for its drugs in North America and domestic markets. WHY IT'S IMPORTANT Indian generic drugmakers Dr. Reddy's Laboratories , Cipla and Sun Pharmaceutical Industries have benefited from strong sales and price recovery in the key U.S. market amid buoyant demand for their generic versions of the blockbuster cancer drug, Revlimid. Analysts expect Lupin to have gained from launch ramp-ups of drugs with limited competition, such as its copycat version of asthma drug Spiriva Handihaler, which was launched by the drugmaker in June 2023. In March, Lupin decided to carve out its trade generics business in India into a separate unit, Lupin Life Sciences. The business sells branded prescription and consumer health products such as immunity supplement Be One capsule. BY THE NUMBERS Consolidated profit after tax rose around 52% to 3.59 billion rupees ($43 million) for the quarter ended March 31, but fell short of ana
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Non-Steroidal Anti-Inflammatory Drugs Market Size to Worth USD 33.55 Bn by 2032 [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- India's Alembic Pharma posts higher Q4 profit on strong N.America sales [Reuters]Reuters
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target raised by analysts at Barclays PLC from $80.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
RDY
Earnings
- 5/8/24 - Beat
RDY
Sec Filings
- 5/17/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- RDY's page on the SEC website